About Angina Pectoris Drugs
Angina is a type of chest pain or discomfort caused due to a coronary heart disease, specifically due to reduced blood flow to the heart. For angina pectoris drugs market, beta blockers remain the most preferred line of treatment. However, the treatment market witnesses a strong presence of other drug classes such as calcium channel blockers. Though the market is fragmented, large players such as AstraZeneca, Gilead, Novartis, and Pfizer hold significant positions.
Technavio’s analysts forecast the global angina pectoris drugs market to grow at a CAGR of 4.05% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global angina pectoris drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Angina Pectoris Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Gilead
• Novartis
• Pfizer
Other prominent vendors
• ABayer HealthCare
• Bristol-Myers Squibb
• GlaxoSmithKline
• Merck
• Mylan
• Teva Pharmaceutical
Market driver
• Increase in chronic diseases
• For a full, detailed list, view our report
Market challenge
• Highly genericized market
• For a full, detailed list, view our report
Market trend
• Launch of novel pharmacologic agents
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Market landscape
• Market overview
• Five forces analysis
PART 06: Pipeline landscape
PART 07: Market segmentation by drug class
• Beta blockers
• Calcium channel blockers
• Nitrates
• Angiotensin-converting enzyme inhibitors
• Others
PART 08: Geographical segmentation
• Market overview based on geography
• Angina pectoris drugs market in Americas
• Angina pectoris drugs market in EMEA
• Angina pectoris market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
• Market drivers
• Market challenges
PART 11: Market trends
• Launch of novel pharmacologic agents
• Genomic medicines
• Growing strategic alliances
PART 12: Vendor landscape
• Competitive landscape
PART 13: Key vendor analysis
• AstraZeneca
• Gilead
• Novartis
• Pfizer
• Other prominent vendors
PART 14: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Major angina types
Exhibit 02: Causes, symptoms, and risk factors for angina pectoris
Exhibit 03: Diagnosis and treatment of angina pectoris
Exhibit 04: Global angina pectoris drugs market snapshot
Exhibit 05: Global angina pectoris drugs market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis of the global angina pectoris drugs market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline molecules by key vendors 2016
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global angina pectoris market by drug class
Exhibit 11: Segmentation of global angina pectoris market by drug class 2016 and 2021
Exhibit 12: Global angina pectoris drugs market by beta blockers 2016-2021 ($ millions)
Exhibit 13: Common beta blockers used in cardiovascular disorders
Exhibit 14: Adverse effects of beta-blockers
Exhibit 15: Global angina pectoris drugs market by calcium channel blockers 2016-2021 ($ millions)
Exhibit 16: Common calcium channel blockers used for angina pectoris
Exhibit 17: Antianginal effects of calcium channel blockers
Exhibit 18: Adverse effects of calcium channel blockers
Exhibit 19: Nitrates for treatment of angina pectoris
Exhibit 20: Global angina pectoris drugs market by nitrates 2016-2021 ($ millions)
Exhibit 21: Effect of nitrates on cardiovascular system
Exhibit 22: Nitroglycerine used for the treatment and prevention of angina pectoris
Exhibit 23: Global angina pectoris drugs market by angiotensin-converting enzyme inhibitors 2016-2021 ($ millions)
Exhibit 24: Adverse effects of angiotensin-converting enzyme inhibitors
Exhibit 25: Other drug classes used for the treatment of angina pectoris
Exhibit 26: Global angina pectoris drugs market by others 2016-2021 ($ millions)
Exhibit 27: Antiplatelet agents used for treatment of angina pectoris
Exhibit 28: Anti-ischemic agent used in treatment of angina pectoris
Exhibit 29: Global angina pectoris drugs market share by geography 2016 and 2021
Exhibit 30: Global angina pectoris drugs market by geography 2016-2021 ($ millions)
Exhibit 31: Market scenario in Americas
Exhibit 32: Angina pectoris drugs market in Americas 2016-2021 ($ millions)
Exhibit 33: Market scenario in EMEA
Exhibit 34: Angina pectoris drugs market in EMEA 2016-2021 ($ millions)
Exhibit 35: Market scenario in APAC
Exhibit 36: Angina pectoris drugs market in APAC 2016-2021 ($ millions)
Exhibit 37: Top Asian countries in terms of population with diabetes
Exhibit 38: World population by age group: 2015-2050 (million)
Exhibit 39: Percentage of population aged 60 and above by region 2015-2050
Exhibit 40: Major complications of diabetes
Exhibit 41: Global obesity facts 2014
Exhibit 42: Competitive structure analysis of global angina pectoris drugs market
Exhibit 43: AstraZeneca: Key highlights
Exhibit 44: AstraZeneca: Strength assessment
Exhibit 45: AstraZeneca: Strategy assessment
Exhibit 46: AstraZeneca: Opportunity assessment
Exhibit 47: Gilead: Key highlights
Exhibit 48: Gilead: Strength assessment
Exhibit 49: Gilead: Strategy assessment
Exhibit 50: Gilead: Opportunity assessment
Exhibit 51: Novartis: Key highlights
Exhibit 52: Novartis: Strength assessment
Exhibit 53: Novartis: Strategy assessment
Exhibit 54: Novartis: Opportunity assessment
Exhibit 55: Pfizer: Key highlights
Exhibit 56: Pfizer: Strength assessment
Exhibit 57: Pfizer: Strategy assessment
Exhibit 58: Pfizer: Opportunity assessment
